info@strategicmarketresearch.com
26, Broadway, Suite 934, New York , 10004
us US: +18317045538    uk UK: +441256636046    in IN: +918260836500
Home » Healthcare » Hormone Replacement Therapy Market Growth Projection, 2030

Hormone Replacement Therapy Market By Therapy Type (Estrogen Hormone Replacement Therapy, Human Growth Hormone Replacement Therapy, Thyroid Hormone Replacement Therapy, Testosterone Hormone Replacement Therapy, Progestogen Hormone Replacement Therapy), Route Of Administration (Oral, Parenteral, Others) By Geography, Size, Forecast, 2021-2030

Published On: Jan-2022   |   Base Year: 2021   |   No Of Pages: 140   |   Historical Data: 2015 - 2019   |   Formats: PDF   |   Report ID: 67307763

Report DescriptionTable of Contents

Industry Statistics and Insights

The global hormone replacement therapy market will witness a robust CAGR of 7.83%, valued at $24.97 billion in 2021, expected to appreciate and reach $49.25 billion by 2030, confirms Strategic Market Research.  

 

Hormone replacement therapy (HRT) is a treatment procedure for replacing and replenishing hormones in the human body that are at inadequate levels compared to those required for normal physiology. The most well-known application of HRT is in the treatment of menopause symptoms. In other words, Hormone replacement therapy is a medical procedure in which patients are given hormones to replace naturally occurring hormones or augment naturally occurring ones that are missing. In the case of females, this treatment is used to restore the hormone levels in women who are at the stage of menopause, allowing the body to operate normally.

 

Hormone replacement therapy (HRT) uses hormones to replace natural hormones when the body's production is insufficient. For instance, hormone replacement therapy is usually given to thyroid patients and human growth hormone patients. Furthermore, HRT was often administered to menopausal women to alleviate indications such as night sweats, hot flushes, sleep disturbances, psychological and genito-urinary disorders (urinary frequency and vaginal dryness), and the prevention of osteoporosis. In addition, a survey of 2,000 American women aged 30 to 60 indicated that approximately 47% of the surveyed population experienced the symptoms of hormonal imbalance in 2019.

 

Menopause is the most frequently reported consequence of age-related hormonal changes. It often begins around the age of 50 in women around the world. By the age of 50, the levels of oestrogen and progesterone produced by women significantly decrease. The pituitary gland compensates for the decline in oestrogen and progesterone production by increasing the output of follicle-stimulating hormone.

 

Hormone Replacement Therapy Based on Market Share-2020

 

Drivers

  • The rise in prevalence of menopausal illness and increased awareness of post-menopausal difficulties among women are two significant factors driving the worldwide HRT market.

  • The hormone replacement therapy market trend is being driven by a large increase in the incidence rate of hormonal abnormalities in newborns, adults, and the elderly. Moreover, disease like The Prader-Willi syndrome (PWS) affects one out of every 15,000 babies.

  • Low-Dosevaginal estrogen therapy, topical estrogen therapy, hysterectomy with bilateral salpingo-oophorectomy, Systemic hormone therapy, and Bioidentical hormone replacement therapy are all the factors that drive the market globally.

 

Restraints

  • During the projected period, unfavorable effects of hormone replacement therapy are expected to restrain market expansion.

  • The high expense of hormone replacement therapy and the risk of acquiring cancer from HRTs are expected to stifle global market growth.

  • Risks involved in hormone replacement therapy include Heart disease, Stroke, Blood clots, and Breast cancer which are expected to restrain the market.

 

Key Opportunity

  • The need for bioidentical hormone replacement therapy and the use of telemedicine for hormone replacement therapy are projected to give a lucrative opportunity for the global hormone replacement therapy market to expand in the near future.

 

Market Analysis Of Different Segments Covered in the Report

By Route Of Administration

  • Oral

  • Parenteral

  • Others

 

Hormone Replacement Therapy Market Based on Therapy Type

 

Hormone Replacement Therapy Market By Therapy Type

  • Estrogen Hormone Replacement Therapy

  • Human Growth Hormone Replacement Therapy

  • Thyroid Hormone Replacement Therapy

  • Testosterone Hormone Replacement Therapy

  • Progestogen Hormone Replacement Therapy

 

By Indication

  • Menopause

  • Hypothyroidism

  • Male Hypogonadism

  • Growth Hormone Deficiency

  • Others

 

By Region

North America

  • United States

  • Canada

  • Mexico

 

Europe

  • Germany

  • France

  • Italy

  • Switzerland

  • UK

  • Rest of Europe

 

Asia-Pacific

  • Japan

  • China

  • India

  • Rest of Asia-Pacific

 

LAMEA

  • Brazil

  • Israel

  • South Africa

  • Saudi Arabia

  • Rest of LAMEA

 

Hormone Replacement Therapy Market Based on Region

Based on Route Of Administration, the oral market segment accounted for the largest proportion of the hormone replacement treatment market in 2020 and is predicted to increase at the quickest rate over the forecast period. This is because oral administration of testosterone medications is highly favored, and oral medication is the most prevalent form of oestrogen replacement therapy.

 

In terms of therapy type, estrogen hormone replacement therapy was the market leader in 2020. This is due to women's increased usage of estradiol products to help them maintain hormonal balance after menopause or hysterectomy. Dryness, burning, itching, and pain during intercourse are some of the vaginal symptoms of menopause that can be alleviated by oestrogen replacement hormone therapy. Estrogen can be taken as a Estrogenpill, gel, Estrogen patch, lotion, or spray. It has a good success rate in treating menopausal night sweats and hot flashes, around 45 percent of women aged 40 to 60 reported seeking medical advice on the benefits and drawbacks of utilizing hormone replacement therapy (HRT) after menopause.

 

Menopause is predicted to expand at the quickest rate in terms of indication from 2021 to 2028, as there is a great advancement in the number of postmenopausal women and the expansion of the menopausal window from 40 to 55 years. In accordance to the American Congress of Obstetricians and Gynecologists, around 6,000 women reach menopause every day.

 

According to World Health Organisation (WHO), around 15 million neonates are born prematurely, with approximately 85% of these children being underdeveloped. Hormone treatment is used in adults to treat disorders like short bowel syndrome and pituitary tumors.

 

The North American market dominated the global hormone replacement therapy market in 2019 due to the rise in manufacturer’s release of various generic hormone replacement therapy medicines, an increase in the target population, and advances in drug delivery technologies, as well as the creation of new formulations. Also, because of the rising public awareness, the hormone replacement treatment market in Asia Pacific is expected to grow quickly in the future years. Emerging countries such as Japan, India, and China will play a significant role in market expansion.

 

According to the NIH(National Institutes of Health), half of the postmenopausal women have used HRT at least once.

 

In 2014, more than 2.5 million Americans received testosterone treatment, according to the American Academy of Family Physicians.

 

In accordance to NIH, about half of all postmenopausal women in the United States had hormone replacement therapy (HRT) at some point in their life. In addition, roughly 1.3 million American women will enter the menopause phase each year by 2021, according to a study published in Statpearls.

 

According to studies conducted by organizations such as Rose Research, the North American Menopause Society (NAMS), and Therapeutic MD, approximately one million women in the United States are currently using hormone replacement therapy, which is expected to rise to 2.5 million in the near future.

 

According to a study published in the Journal of Menopausal Medicine in 2020, about 75 percent of women experience menopause symptoms between the ages of 45 and 55, resulting in decreased self-esteem.

 

According to the World Population Ageing 2019 study, women will account for 54 percent of the global population aged 65 and over by 2050, with a life expectancy at birth of 74.7 years in 2019.

 

According to the American Thyroid Association (ATA), more than 12% of the US population is expected to have a thyroid issue during their lifetime, and nearly 20 million Americans are impacted by thyroid illness each year. As a result of the significant prevalence of thyroid hormone imbalance among the people in the United States, the studied market in the region is predicted to grow.

 

Hormone Replacement Therapy Market Competitive Landscape Analysis

Hormone Replacement Therapy Market Report Coverage

Report Attribute

Details

Forecast Period

2021 - 2030

The market size value in 2021

USD 24.97 billion

The revenue forecast in 2030

USD 49.25 billion

Growth rate

CAGR of approximately  7.839%

The base year for estimation

2021

Historical data

2015 – 2019

Unit

USD Billion, CAGR (2021 - 2030)

Segmentation

By Route Of Administration, By Therapy Type, By Indication, By Region

By Route Of Administration

Oral, Parenteral, Others

By Therapy Type

Estrogen Hormone Replacement Therapy, Human Growth Hormone Replacement Therapy, Thyroid Hormone Replacement Therapy, Testosterone Hormone Replacement Therapy, Progestogen Hormone Replacement Therapy

By Indication

Menopause, Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, Others

By Region

North America, Asia-Pacific, Europe, LAMEA

Country Scope

United States of America, Mexico, United Arab Emirates, United Kingdom, Germany, France, Canada, China, India, Japan, South Korea, Brazil, Argentina, Saudi Arabia, South Africa

Company Usability Profiles

Abbott Laboratories, Bayer Ag., Eli Lily And Company, Hoffmann-La Roche Ltd. (Genentech, Inc.), Hisamitsu Pharmaceutical Co., Inc. (Noven Pharmaceuticals, Inc.), Merck Kgaa, Mylan N.V. (Viatris Inc.), Novartis International Ag, Novo Nordisk A/S, Pfizer Inc.

 

Recent Developments

  • On August 16th, 2022, Akorn announced that it had successfully received FDA approval for launching its Generic-Cetrorelix Acetate in the form of Injection (0.25 mg quantity). Cetrorelix is one of the most effective chemicals used in hormone replacement therapy as it totally blocks the adverse impacts of a natural hormone, known as GnRH or gonadotropin-releasing hormone. During the treatment process of ovarian stimulation, premature ovulation can lead to the formation of eggs that are unsuitable for fertilization. The Cetrorelix Acetate present in the Injection blocks such kind of premature ovulation.

  • In December 2020, The US FDA approved Myovant Sciences' Orgovyx (relugolix). Orgovyx (relugolix) is an orally administered treatment that prevents the pituitary gland from producing luteinizing hormone and follicle-stimulating hormone, decreasing the amount of testosterone produced by the testicles. This aids in the treatment of advanced prostate cancer in adults.

  • In August 2020, Bayer AG announced the acquisition of KanDy Therapeutics Inc., which will help Bayer to expand its women's medicine pipeline by including menopausal treatment in its portfolio.

  • In August 2020, the FDA (US Food and Drug Administration) authorized Sogroya (somapacitan), a human growth hormone (HGH) therapy for adults with growth hormone insufficiency that is administered once a week via injection under the skin. As a result, the region's analyzed market is projected to be driven by the high trend of product approvals.

 

The Key Products that the Market Leaders Develop

Name of the product

Function

Key Players

THYROCAB

It is used in curing hyperthyroidism

Abbott Laboratories

 

ANGELIQ

It is used to reduce menopause symptoms

Bayer Inc.

Adakveo

It is used to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients.

Novartis International Ag

 

Frequently Asked Question About This Report

b: The global hormone replacement therapy market is expected to grow at a compound annual growth rate (CAGR) of 7.839% from 2021 to 2030 to reach USD $ 49.25 billion by 2030.

b: The global hormone replacement therapy market size was $24.97 billion in 2021 and is predicted to reach $49.25 billion by 2030, with a CAGR of 7.83%.

b: According to indication, the menopausal segment would grow at the quickest rate throughout the projected period, due to an increasing advancement in the number of postmenopausal women and the expansion of the menopausal window from 40 to 55 years.

b: The key players majorly operating in the Hormone Replacement Therapy Market areAbbott Laboratories, Bayer Ag.Eli Lily And Company, Pfizer Inc., Hisamitsu Pharmaceutical Co., Hoffmann-La Roche Ltd. (Genentech, Inc.), Inc. (Noven Pharmaceuticals, Inc.), Merck Kgaa, Mylan N.V. (Viatris Inc.), Novartis International Ag, Novo Nordisk A/S,

b: In terms of therapy type, oestrogen hormone replacement therapy was the market leader in 2021.

b: The oral category accounted for the greatest proportion of the market in 2021

Sources

https://www.un.org/en/development/desa/population/publications/pdf/ageing/WorldPopulationAgeing2019-Highlights.pdf

https://www.who.int/news-room/fact-sheets/detail/preterm-birth

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963523/

https://www.statpearls.com/ArticleLibrary/viewarticle/27522

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830366/